Javascript doit fonctionner ! Activez-le et rechargez cette page.
Le Rézo de JeuxDeMots
• Types de relations
• Types de noeuds
• Consolider
le terme
  Options  
             

  Filtrage type relations : +   - (ex: 4, 12, 18, 36, 444, 555, 777)
  Filtrage valeur :          min   max
  Filtrage type noeuds :   +   - (ex: 4, 6, 8, 9, 10, 12, 18, 36, 444, 555, 777)

  Présentation de sortie :   (ex: -rien-, cloud, nicecloud)
 

'en:hla-dp beta-chains'
(id=6739737 ; fe=en:hla-dp beta-chains ; type=1 ; niveau=200 ; luminosité=25 ; somme entrante=1240 creation date=2017-06-22 touchdate=2024-09-16 04:22:53.000)
≈ 43 relations sortantes

  1. en:hla-dp beta-chains -- r_associated #0: 42 / 1 -> en:hla-dpb1*03:02 antigen
    n1=en:hla-dp beta-chains | n2=en:hla-dpb1*03:02 antigen | rel=r_associated | relid=0 | w=42
  2. en:hla-dp beta-chains -- r_associated #0: 38 / 0.905 -> en:in cerebrospinal fluid
    n1=en:hla-dp beta-chains | n2=en:in cerebrospinal fluid | rel=r_associated | relid=0 | w=38
  3. en:hla-dp beta-chains -- r_associated #0: 37 / 0.881 -> en:hla-dp alpha-chains
    n1=en:hla-dp beta-chains | n2=en:hla-dp alpha-chains | rel=r_associated | relid=0 | w=37
  4. en:hla-dp beta-chains -- r_associated #0: 35 / 0.833 -> en:drug effect
    n1=en:hla-dp beta-chains | n2=en:drug effect | rel=r_associated | relid=0 | w=35
  5. en:hla-dp beta-chains -- r_associated #0: 35 / 0.833 -> en:hla-dpb1*02:01:04 antigen
    n1=en:hla-dp beta-chains | n2=en:hla-dpb1*02:01:04 antigen | rel=r_associated | relid=0 | w=35
  6. en:hla-dp beta-chains -- r_associated #0: 34 / 0.81 -> en:hla-dp4 antigen
    n1=en:hla-dp beta-chains | n2=en:hla-dp4 antigen | rel=r_associated | relid=0 | w=34
  7. en:hla-dp beta-chains -- r_associated #0: 34 / 0.81 -> en:mechanism of action qualifier
    n1=en:hla-dp beta-chains | n2=en:mechanism of action qualifier | rel=r_associated | relid=0 | w=34
  8. en:hla-dp beta-chains -- r_associated #0: 32 / 0.762 -> en:aspects of adverse effects
    n1=en:hla-dp beta-chains | n2=en:aspects of adverse effects | rel=r_associated | relid=0 | w=32
  9. en:hla-dp beta-chains -- r_associated #0: 32 / 0.762 -> en:aspects of radiation effects
    n1=en:hla-dp beta-chains | n2=en:aspects of radiation effects | rel=r_associated | relid=0 | w=32
  10. en:hla-dp beta-chains -- r_associated #0: 32 / 0.762 -> en:historical aspects qualifier
    n1=en:hla-dp beta-chains | n2=en:historical aspects qualifier | rel=r_associated | relid=0 | w=32
  11. en:hla-dp beta-chains -- r_associated #0: 32 / 0.762 -> en:hla-dp antigen
    n1=en:hla-dp beta-chains | n2=en:hla-dp antigen | rel=r_associated | relid=0 | w=32
  12. en:hla-dp beta-chains -- r_associated #0: 32 / 0.762 -> en:hla-dpb1*04:01 antigen
    n1=en:hla-dp beta-chains | n2=en:hla-dpb1*04:01 antigen | rel=r_associated | relid=0 | w=32
  13. en:hla-dp beta-chains -- r_associated #0: 32 / 0.762 -> en:hla-dpb1*116:01 antigen
    n1=en:hla-dp beta-chains | n2=en:hla-dpb1*116:01 antigen | rel=r_associated | relid=0 | w=32
  14. en:hla-dp beta-chains -- r_associated #0: 32 / 0.762 -> en:immunology aspects
    n1=en:hla-dp beta-chains | n2=en:immunology aspects | rel=r_associated | relid=0 | w=32
  15. en:hla-dp beta-chains -- r_associated #0: 31 / 0.738 -> en:hla-dpb1*85:01 antigen
    n1=en:hla-dp beta-chains | n2=en:hla-dpb1*85:01 antigen | rel=r_associated | relid=0 | w=31
  16. en:hla-dp beta-chains -- r_associated #0: 31 / 0.738 -> en:hla-dpb1*97:01 antigen
    n1=en:hla-dp beta-chains | n2=en:hla-dpb1*97:01 antigen | rel=r_associated | relid=0 | w=31
  17. en:hla-dp beta-chains -- r_associated #0: 31 / 0.738 -> en:hla-dpw2 antigen
    n1=en:hla-dp beta-chains | n2=en:hla-dpw2 antigen | rel=r_associated | relid=0 | w=31
  18. en:hla-dp beta-chains -- r_associated #0: 31 / 0.738 -> en:metabolic aspects
    n1=en:hla-dp beta-chains | n2=en:metabolic aspects | rel=r_associated | relid=0 | w=31
  19. en:hla-dp beta-chains -- r_associated #0: 30 / 0.714 -> en:exposure as collected domain
    n1=en:hla-dp beta-chains | n2=en:exposure as collected domain | rel=r_associated | relid=0 | w=30
  20. en:hla-dp beta-chains -- r_associated #0: 30 / 0.714 -> en:hla-dpb1*02:02 antigen
    n1=en:hla-dp beta-chains | n2=en:hla-dpb1*02:02 antigen | rel=r_associated | relid=0 | w=30
  21. en:hla-dp beta-chains -- r_associated #0: 30 / 0.714 -> en:hla-dpb1*04:02 antigen
    n1=en:hla-dp beta-chains | n2=en:hla-dpb1*04:02 antigen | rel=r_associated | relid=0 | w=30
  22. en:hla-dp beta-chains -- r_associated #0: 30 / 0.714 -> en:hla-dpb1*04:03 antigen
    n1=en:hla-dp beta-chains | n2=en:hla-dpb1*04:03 antigen | rel=r_associated | relid=0 | w=30
  23. en:hla-dp beta-chains -- r_associated #0: 30 / 0.714 -> en:hla-dpb1*90:01 antigen
    n1=en:hla-dp beta-chains | n2=en:hla-dpb1*90:01 antigen | rel=r_associated | relid=0 | w=30
  24. en:hla-dp beta-chains -- r_associated #0: 30 / 0.714 -> en:hla-dpw3 antigen
    n1=en:hla-dp beta-chains | n2=en:hla-dpw3 antigen | rel=r_associated | relid=0 | w=30
  25. en:hla-dp beta-chains -- r_associated #0: 30 / 0.714 -> en:poisoning aspects
    n1=en:hla-dp beta-chains | n2=en:poisoning aspects | rel=r_associated | relid=0 | w=30
  26. en:hla-dp beta-chains -- r_associated #0: 30 / 0.714 -> en:ultrastructure
    n1=en:hla-dp beta-chains | n2=en:ultrastructure | rel=r_associated | relid=0 | w=30
  27. en:hla-dp beta-chains -- r_associated #0: 29 / 0.69 -> en:hla-dpb1*09:01 antigen
    n1=en:hla-dp beta-chains | n2=en:hla-dpb1*09:01 antigen | rel=r_associated | relid=0 | w=29
  28. en:hla-dp beta-chains -- r_associated #0: 29 / 0.69 -> en:in blood
    n1=en:hla-dp beta-chains | n2=en:in blood | rel=r_associated | relid=0 | w=29
  29. en:hla-dp beta-chains -- r_associated #0: 28 / 0.667 -> en:analysis aspect
    n1=en:hla-dp beta-chains | n2=en:analysis aspect | rel=r_associated | relid=0 | w=28
  30. en:hla-dp beta-chains -- r_associated #0: 28 / 0.667 -> en:genetic aspects
    n1=en:hla-dp beta-chains | n2=en:genetic aspects | rel=r_associated | relid=0 | w=28
  31. en:hla-dp beta-chains -- r_associated #0: 28 / 0.667 -> en:hla-dpb1*05:01 antigen
    n1=en:hla-dp beta-chains | n2=en:hla-dpb1*05:01 antigen | rel=r_associated | relid=0 | w=28
  32. en:hla-dp beta-chains -- r_associated #0: 28 / 0.667 -> en:in urine
    n1=en:hla-dp beta-chains | n2=en:in urine | rel=r_associated | relid=0 | w=28
  33. en:hla-dp beta-chains -- r_associated #0: 28 / 0.667 -> en:physiological aspects
    n1=en:hla-dp beta-chains | n2=en:physiological aspects | rel=r_associated | relid=0 | w=28
  34. en:hla-dp beta-chains -- r_associated #0: 28 / 0.667 -> en:therapeutic use - qualifier
    n1=en:hla-dp beta-chains | n2=en:therapeutic use - qualifier | rel=r_associated | relid=0 | w=28
  35. en:hla-dp beta-chains -- r_associated #0: 28 / 0.667 -> en:toxicity aspects
    n1=en:hla-dp beta-chains | n2=en:toxicity aspects | rel=r_associated | relid=0 | w=28
  36. en:hla-dp beta-chains -- r_associated #0: 27 / 0.643 -> en:bioformation
    n1=en:hla-dp beta-chains | n2=en:bioformation | rel=r_associated | relid=0 | w=27
  37. en:hla-dp beta-chains -- r_associated #0: 27 / 0.643 -> en:contraindications aspect
    n1=en:hla-dp beta-chains | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=27
  38. en:hla-dp beta-chains -- r_associated #0: 27 / 0.643 -> en:hla class ii histocompatibility antigen, dp(w4) beta chain
    n1=en:hla-dp beta-chains | n2=en:hla class ii histocompatibility antigen, dp(w4) beta chain | rel=r_associated | relid=0 | w=27
  39. en:hla-dp beta-chains -- r_associated #0: 27 / 0.643 -> en:hla-dpb1*02:01 antigen
    n1=en:hla-dp beta-chains | n2=en:hla-dpb1*02:01 antigen | rel=r_associated | relid=0 | w=27
  40. en:hla-dp beta-chains -- r_associated #0: 27 / 0.643 -> en:hla-dpw1 antigen
    n1=en:hla-dp beta-chains | n2=en:hla-dpw1 antigen | rel=r_associated | relid=0 | w=27
  41. en:hla-dp beta-chains -- r_associated #0: 26 / 0.619 -> en:chemical aspects
    n1=en:hla-dp beta-chains | n2=en:chemical aspects | rel=r_associated | relid=0 | w=26
  42. en:hla-dp beta-chains -- r_associated #0: 26 / 0.619 -> en:taxonomic
    n1=en:hla-dp beta-chains | n2=en:taxonomic | rel=r_associated | relid=0 | w=26
  43. en:hla-dp beta-chains -- r_associated #0: 20 / 0.476 -> effet d'un médicament
    n1=en:hla-dp beta-chains | n2=effet d'un médicament | rel=r_associated | relid=0 | w=20
≈ 44 relations entrantes

  1. en:hla-dpb1*02:01 antigen --- r_associated #0: 43 --> en:hla-dp beta-chains
    n1=en:hla-dpb1*02:01 antigen | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=43
  2. en:physiological aspects --- r_associated #0: 35 --> en:hla-dp beta-chains
    n1=en:physiological aspects | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=35
  3. en:bioformation --- r_associated #0: 34 --> en:hla-dp beta-chains
    n1=en:bioformation | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=34
  4. en:hla-dpw1 antigen --- r_associated #0: 34 --> en:hla-dp beta-chains
    n1=en:hla-dpw1 antigen | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=34
  5. en:hla class ii histocompatibility antigen, dp(w4) beta chain --- r_associated #0: 32 --> en:hla-dp beta-chains
    n1=en:hla class ii histocompatibility antigen, dp(w4) beta chain | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=32
  6. en:hla-dpb1*02:01:04 antigen --- r_associated #0: 32 --> en:hla-dp beta-chains
    n1=en:hla-dpb1*02:01:04 antigen | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=32
  7. en:hla-dpb1*85:01 antigen --- r_associated #0: 32 --> en:hla-dp beta-chains
    n1=en:hla-dpb1*85:01 antigen | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=32
  8. en:hla-dpb1*90:01 antigen --- r_associated #0: 32 --> en:hla-dp beta-chains
    n1=en:hla-dpb1*90:01 antigen | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=32
  9. en:hla-dpw2 antigen --- r_associated #0: 32 --> en:hla-dp beta-chains
    n1=en:hla-dpw2 antigen | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=32
  10. en:hla-dp alpha-chains --- r_associated #0: 31 --> en:hla-dp beta-chains
    n1=en:hla-dp alpha-chains | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=31
  11. en:hla-dpb1*04:01 antigen --- r_associated #0: 31 --> en:hla-dp beta-chains
    n1=en:hla-dpb1*04:01 antigen | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=31
  12. effet d'un médicament --- r_associated #0: 30 --> en:hla-dp beta-chains
    n1=effet d'un médicament | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=30
  13. en:aspects of radiation effects --- r_associated #0: 30 --> en:hla-dp beta-chains
    n1=en:aspects of radiation effects | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=30
  14. en:drug effect --- r_associated #0: 30 --> en:hla-dp beta-chains
    n1=en:drug effect | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=30
  15. en:hla-dpb1*04:03 antigen --- r_associated #0: 30 --> en:hla-dp beta-chains
    n1=en:hla-dpb1*04:03 antigen | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=30
  16. en:hla-dpb1*02:02 antigen --- r_associated #0: 29 --> en:hla-dp beta-chains
    n1=en:hla-dpb1*02:02 antigen | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=29
  17. en:hla-dpb1*97:01 antigen --- r_associated #0: 29 --> en:hla-dp beta-chains
    n1=en:hla-dpb1*97:01 antigen | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=29
  18. en:hla-dpw3 antigen --- r_associated #0: 29 --> en:hla-dp beta-chains
    n1=en:hla-dpw3 antigen | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=29
  19. en:mechanism of action qualifier --- r_associated #0: 29 --> en:hla-dp beta-chains
    n1=en:mechanism of action qualifier | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=29
  20. en:toxicity aspects --- r_associated #0: 29 --> en:hla-dp beta-chains
    n1=en:toxicity aspects | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=29
  21. en:hla-dpb1*04:02 antigen --- r_associated #0: 28 --> en:hla-dp beta-chains
    n1=en:hla-dpb1*04:02 antigen | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=28
  22. en:hla-dpb1*116:01 antigen --- r_associated #0: 28 --> en:hla-dp beta-chains
    n1=en:hla-dpb1*116:01 antigen | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=28
  23. en:chemical aspects --- r_associated #0: 27 --> en:hla-dp beta-chains
    n1=en:chemical aspects | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=27
  24. en:contraindications aspect --- r_associated #0: 27 --> en:hla-dp beta-chains
    n1=en:contraindications aspect | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=27
  25. en:exposure as collected domain --- r_associated #0: 27 --> en:hla-dp beta-chains
    n1=en:exposure as collected domain | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=27
  26. en:hla-dp antigen --- r_associated #0: 27 --> en:hla-dp beta-chains
    n1=en:hla-dp antigen | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=27
  27. en:hla-dpb1*03:02 antigen --- r_associated #0: 27 --> en:hla-dp beta-chains
    n1=en:hla-dpb1*03:02 antigen | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=27
  28. en:hla-dpb1*05:01 antigen --- r_associated #0: 27 --> en:hla-dp beta-chains
    n1=en:hla-dpb1*05:01 antigen | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=27
  29. en:hla-dpb1*09:01 antigen --- r_associated #0: 27 --> en:hla-dp beta-chains
    n1=en:hla-dpb1*09:01 antigen | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=27
  30. en:immunology aspects --- r_associated #0: 27 --> en:hla-dp beta-chains
    n1=en:immunology aspects | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=27
  31. en:hla-dp4 antigen --- r_associated #0: 26 --> en:hla-dp beta-chains
    n1=en:hla-dp4 antigen | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=26
  32. en:in blood --- r_associated #0: 26 --> en:hla-dp beta-chains
    n1=en:in blood | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=26
  33. en:metabolic aspects --- r_associated #0: 26 --> en:hla-dp beta-chains
    n1=en:metabolic aspects | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=26
  34. en:poisoning aspects --- r_associated #0: 26 --> en:hla-dp beta-chains
    n1=en:poisoning aspects | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=26
  35. en:taxonomic --- r_associated #0: 26 --> en:hla-dp beta-chains
    n1=en:taxonomic | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=26
  36. en:therapeutic use - qualifier --- r_associated #0: 26 --> en:hla-dp beta-chains
    n1=en:therapeutic use - qualifier | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=26
  37. en:aspects of adverse effects --- r_associated #0: 25 --> en:hla-dp beta-chains
    n1=en:aspects of adverse effects | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=25
  38. en:historical aspects qualifier --- r_associated #0: 25 --> en:hla-dp beta-chains
    n1=en:historical aspects qualifier | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=25
  39. en:in urine --- r_associated #0: 25 --> en:hla-dp beta-chains
    n1=en:in urine | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=25
  40. en:genetic aspects --- r_associated #0: 24 --> en:hla-dp beta-chains
    n1=en:genetic aspects | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=24
  41. en:ultrastructure --- r_associated #0: 24 --> en:hla-dp beta-chains
    n1=en:ultrastructure | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=24
  42. en:analysis aspect --- r_associated #0: 23 --> en:hla-dp beta-chains
    n1=en:analysis aspect | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=23
  43. en:in cerebrospinal fluid --- r_associated #0: 23 --> en:hla-dp beta-chains
    n1=en:in cerebrospinal fluid | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=23
  44. taxinomique --- r_associated #0: 10 --> en:hla-dp beta-chains
    n1=taxinomique | n2=en:hla-dp beta-chains | rel=r_associated | relid=0 | w=10
Le service Rézo permet d'énumérer les relations existant pour un terme. Ce service est interrogeable par programme.
Projet JeuxDeMots - url: http://www.jeuxdemots.org
contact: mathieu.lafourcade@lirmm.fr